During the past decade, Suite 502 conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Suite 502" are "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Suite 502" in a lesser frequency.

Most popular intervention types in "Suite 502" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials) and "bococizumab (PF-04950615)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Suite 502" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Suite 502". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Suite 502, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Suite 502, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".